Method for treating the cases of periodontitis

FIELD: medicine.

SUBSTANCE: method involves covering lesion focus with cell containing dialysis solution composed of Dimexid, antibiotic, 0.1% potassium furagin and 25% glucose solution taken in 1:4:3:2 proportion. The cell is fixed on teeth with ligature. Cell wall adjacent to gingiva is covered with semipermeable Cuprofan membrane and the opposite wall with latex rubber. Dialysis is carried out 20 min long twice a day.

EFFECT: enhanced effectiveness of treatment; retained natural protection factors; reduced edema and inflammation manifestations.

 

The present invention relates to medicine, namely dentistry.

There are various ways of treating periodontal disease.

There is a method by which the affected area is lined with gauze wipes moistened with a solution of the antibiotic. The active electrode is fixed on the gums in the affected area, and passive in the neck. The time of electrophoresis 20-30 min 8-10 procedures (see Luesebrink, Raspados. "Issues of Spa dentistry", issue 1, Essentuki, 1958, p.119-127). However, this method is contraindicated in intolerance of electric current and in the presence of ulcerations. This method provides the ability to enter in the mucous membrane of the gums medicinal substance, but does not allow you to remove the products of the decay of tissues.

Closest to the proposed method is a method of treatment with bandages from the official ointments adding equal proportions of white clay and water dentin. The composition is kneaded to the consistency of thick cream, put on dried and isolated with cotton swabs gum thin layer (Navkratia, Trakhterov "periodontal Disease", N. Novgorod, Publishing house C, 2000, p.86). More complex dressings consist of zinc oxide, rosin, tannin, white clay, zinc acetate, clove, flax, corn oils in equal proportions and, for example, but is of sulfate. Such complex dressings are used very rarely.

However, the known method does not have high efficiency because it is difficult to dispense the drug, and the concentration of the medicinal substance is continuously decreasing due to erosion headbands saliva. Antibacterial drugs that are included in bandages, via saliva affect not only the pathogenic microflora of inflammation, but also on the microflora of the oral cavity and upper gastrointestinal tract, causing an imbalance. In addition, after hardening bandage becomes a monolith, preventing the outflow of inflammation.

The technical result of the proposed method of treating periodontal disease is a term reduction of inflammation in the periodontium due to local effects.

New in the achievement of the technical result is that the gums in the area of injury impose a cuvette containing dialysis solution and fix it to the teeth by the ligature.

New is also that the wall of the cell, adjacent to the gum, closed semi-permeable membrane, for example, of cuprofen, and the opposite wall latex rubber.

What is new is that the dialysis is carried out twice a day for 20 minutes.

New is also that the dialysis solution consists of a solution of Dimexidum, antibiotic, FSD is part of an hin of potassium 0.1% glucose 25% in the following ratio: 1:4:3:2.

The use of dialysis for the treatment of periodontitis allows locally to influence the lesion, allows you to adjust the impact zone, which allows to improve the clinical effect of treatment.

The use of semi-permeable membrane, for example, of cuprofen in a ditch allows you to enter low-molecular substances, while maintaining a given concentration of the drug throughout the procedure, to eliminate contact of the drug with other departments of the mucous membranes of the oral cavity, preventing the occurrence of imbalance of microflora in these departments. You can use multi-component solutions, affecting several parts of the pathogenesis process. If dialysis) outflow from a lesion of low molecular weight products of tissue destruction and the preservation of the natural protective factors, which results in more rapid clearance of the lesion, reducing the swelling and inflammation of the gums.

The composition of the dialysis solution has antibacterial, antitumor, anti-inflammatory effect, promotes the penetration and accumulation of the components of the solution in the lesion, which reduces inflammation.

Dialysis for 20 minutes twice a day can reach the optimal concentration of the dialysis solution in the lesion

Comparative analysis of the proposed solutions and prototype shows that the inventive method differs from the gums in the area of injury impose a cuvette containing dialysis solution and fix it to the teeth by the ligature, and the wall of the cell adjacent to the gum, closed semi-permeable membrane, for example, of cuprofen, but the opposite latex rubber. While dialysis is conducted for 20 minutes twice a day, dialysis solution consists of a solution of Dimexidum, antibiotic, furagin potassium 0.1% glucose 25%, with the following ratio of components 1:4:3:2, which corresponds to the criteria of the invention of "novelty."

A new set of features ensures a reduction in terms of relief of the inflammatory process in the periodontal due to local multicomponent impact, preservation of therapeutic drug concentrations, removal of products of tissue decay of the hearth and store natural protective factors, which meets the criterion of "industrial applicability".

The method is as follows.

After elimination of local irritating factors (calculus, defective fillings, and dentures) the patient get the impression of the jaw and cast models. From the wax model base of the cell frame and replace the wax on dental plastic. The wall of the cuvette, pile asuu to the gum, close semi-permeable membrane of cuprophan. The opposite wall is closed with a latex rubber and fill the cuvette dialysis solution. A cell placed on the gums in the area of injury and fix by means of ligatures to the neighboring teeth. Dialysis solution consists of a solution of Dimexidum - 1 part, antibiotic (on the sensitivity of microflora of periodontal pocket) - 4 pieces, furagin potassium of 0.1% to 3 parts, glucose 25% - 2 parts, i.e. in the ratio 1:4:3:2. Dialysis spend 20 minutes twice a day. To do this, the patient is given a house filled cell.

The method is illustrated in the following clinical example.

Patient, 46 years old, came with complaints of bleeding gums, increased deposition of Tartar, bad breath.

History: bleeding noticed about 5 years ago. The periodontist has not previously been addressed. Suffering from hypertension. Engaged in self: put trichopol to the gum, which was inefficient.

Objective: the gingival papillae and the edge of the upper and lower jaw hypermonogenic, swollen, bleeding upon probing. Rich deposits of Tartar in the field 16, 15, 11, 21, 24, 25, 31, 32, 33, 34, 35, 36, 41, 42, 43, 44, 45, 46, 47 teeth. Hygienic index on the Fedorov-volodkina and 2.9. In the field of 11 notes periodontal pocket depth 7 mm with purulent discharge; 12, 21 who UPOV - 5 mm Recession of the gingival margin by 1 mm area 11. In the area of the remaining teeth periodontal pocket depth of 4 mm

On the orthopantomogram: bone resorption millionary partitions on1/2the length of the tooth root in the field of 11 and 21, in the region of 12 and 22 from 1/3 to 1/2, the disappearance of the cortical plate all over.

Diagnosis: Chronic generalized periodontitis medium-severe, acute stage.

Treatment: after removal of local irritants and determine the sensitivity of microflora of periodontal pockets to antibiotics on the gum area 12, 11, 21, 22 teeth fixed cuvette containing dialysis solution containing dimexide, 30% of lincomycin hydrochloride, 0.1% furagin potassium, 25% glucose in the ratio 1:4:3:2. Treatment time 20 minutes twice a day (cuvette was issued for the house).

On the 3rd day of treatment decreased gnetaceae and almost disappeared bleeding, on the 5th day of the inflammatory process was stopped, the patient has a further surgical treatment.

Thus, the proposed method of treatment allows you to save an effective therapeutic concentration within treatments and between them, allows to eliminate the contact of the solution with other departments of the mucous membranes of the oral cavity (except gum) and to regulate the impact zone. Produces dialysis solution allows the t to achieve synergistic effects of antibacterial drugs and affect multiple stages of pathogenesis process. The proposed method allows to remove from the lesion of low molecular weight breakdown products of tissues, while preserving the natural protective factors.

A method of treating periodontal disease by applying on the affected area of the medical bandage, characterized in that on the gums in the area of injury impose a cuvette containing dialysis solution consisting of solutions of Dimexidum, antibiotic, furagin potassium 0.1% glucose 25% in the following ratio of components 1:4:3:2, and fixed to the teeth by the ligature, and the wall of the cell adjacent to the gum, closed semi-permeable membrane of cuprofen, and the opposite wall - latex rubber, and the dialysis is conducted for 20 min twice a day.



 

Same patents:

Modified chitosan // 2269542

FIELD: organic chemistry of natural compounds, chemical technology, medicine.

SUBSTANCE: invention relates to the group of chitosan-containing compounds. Invention relates to synthesis of modified chitosan of the following structure: wherein n = 150-1400. The modified chitosan possesses the bactericidal activity, in particular, antituberculosis activity.

EFFECT: valuable medicinal properties of modified chitosan.

1 tbl, 1 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with technique of revaccination in adults against diphtheria and tetanus under conditions of Far North. For this purpose one should form a group of people vaccinated more than 10 years ago to vaccinate them in February. The method leads to increased efficiency of vaccination due to decreased duration of vaccination period.

EFFECT: higher efficiency of revaccination.

7 ex

FIELD: medicine, obstetrics.

SUBSTANCE: one should conduct antibacterial therapy 3 mo before planned pregnancy consisting of preparations of tetracyclinic group or macrolides in combination with nystatin and metronidasol to continue it since the first day of menstrual cycle and, also, it is necessary to perform correction of vaginal biocenosis, and about 3-4 wk after therapy carried out for 2 next mo before planned pregnancy starting, also, since the first day of menstrual cycle - metabolic therapy; At the onset of pregnancy one should conduct courses for preventing placental deficiency dealing with introduction of preparations that improve uterine-placental circulation, and preparations that improve rheological properties of blood and vitamin-metabolic therapy or the same preparations, and additionally - introduction of macrolides ad viferon rectally in case of activation of chlamydial infection. The present innovation enables to sanitize uterine cavity, improve uterine-placental circulation, restoration of placental tissue structure that, in its turn favors the birth of healthy generation.

EFFECT: higher efficiency of prophylaxis.

1 cl, 9 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: medicinal formulation possessing the bacteristatic effect consists of a core comprising the following components, wt.-%: clarithromycin, 40.0-80.0; polyvinylpyrrolidone, 3.0-10.0; sodium lauryl sulfate, 2.0-5.0; sodium croscarmelose, 4.0-10.0; aerosil, 0.5-2.0; magnesium stearate, 0.5-2.0, and microcrystalline cellulose, 10.0-31.0. Also, the medicinal formulation consists of envelope comprising the following components, wt.-%: hydroxypropylmethylcellulose, 30.0-70.0; polyethylene glycol, 12.0-22.0; titanium dioxide, 11.0-20.0, hydroxypropylcellulose, 2.0-10.0, dye yellow quinoline, 1.0-4.0, and vanillin, 1.0-4.0. Also, invention describes a method for preparing the medicinal formulation by wet granulation followed by tableting and applying the envelope from an aqueous suspension. Prepared tablets show the necessary mechanical strength, insignificant scattering index by mass (± 3.5%) and dissolving 88-91% for 30 min.

EFFECT: improved and valuable properties of medicinal formulation.

3 cl, 2 tbl

FIELD: medicine, gynecology, surgery.

SUBSTANCE: one should introduce 3.5%-chitosan ascorbate gel into fistulous channel that contains metronidasol at the dosage of 2 mg/ml, at the volume up to 20 ml once/2 d till complete fistula's closing. The present innovation enables to activate reparative processes and fistulous epithelization that favors for closing fistulous channel in earlier terms.

EFFECT: higher efficiency of therapy conducted.

2 ex

FIELD: medicine, surgery.

SUBSTANCE: one should apply a polycompositional film onto donor's wounds after autodermoplasty performed. This film contains the following components in weight proportions: chitosan 78.3-89.4; polyvinyl alcohol 9.8-19.8; antibiotic of aminoglycoside group 0.5-2.0; anesthetic 0.1-0.2. It is perforated at tension coefficient being 1:4. The innovation enables to decrease wound's traumatization, improves prophylaxis of suppuration and increases cosmetic effect even at a single application of the film suggested.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with application of pleuromutilin derivatives, that is valnemulin and thiamulin, for transdermal treatment of bacterial diseases, in particular those induced by Dichelobacter nodosus, Fusobacterium necrophorum, Bacteriodes nodosus and Bacteriodes melamnogenicus, for manufacturing medicinal preparation or as an active ingredient of medicinal preparation of the same indication and corresponding method for transdermal treatment of diseases, for example foot rot. It has been detected the capacity of antibiotics to penetrate skin and enter either plasma or blood at concentrations being efficient against systemic bacterial infections, so, medicinal preparation could be designed in the form of ointment, cream, solution, shampoo, powder and spray.

EFFECT: higher efficiency of application.

9 cl, 1 tbl

FIELD: biotechnology, immunology.

SUBSTANCE: invention proposes preparation that comprises the immunoelectrophoretically pure secretory immunoglobulin A isolated from whey milk and/or colostrum of immunized ungulate animals and pharmaceutically acceptable vehicles. The base preparation (substance) comprises 6-12% of secretory immunoglobulin A at pH 4-8, an anti-complementary activity at least 10 mg of protein, not activating 2 CH50, protects in >70% against corresponding infections (in infection macroorganism in doses ≥10 ID50), shows areactogenic property in intravenous administration, can comprise stabilizing additives in the total concentration 4%, not above. The preparation possesses high purity, low anti-complementary activity, stable in storage, useful for oral, parenteral and topical using and possesses therapeutic activity with respect to microorganisms and viruses against which humans and animals immunization have been carried out. Invention can be used in treatment and prophylaxis of immunodeficiency states, bacterial and viral infections in humans and animals.

EFFECT: valuable medicinal and veterinary properties of preparation.

9 cl, 1 tbl, 10 ex

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to novel heterocyclic compounds comprising 2-aminopyridin-3-sulfonic fragment of the general formula (1) or their pharmaceutically acceptable salts, N-oxides or hydrates possessing properties of antagonists of glutamate-induced calcium ions transport, in particular, neuroprotective effect. Also, invention relates to the focused library for the search of biologically active leader-compounds comprising at least one heterocyclic compound of the general formula (1) and to pharmaceutical composition if form of tablets, capsules or injections placed into pharmaceutically acceptable package containing compounds of invention as an active substance. In compound of the general formula (1) R1 represents hydrogen atom; R2 represents chlorine atom, optionally substituted hydroxyl group, optionally substituted amino-group, optionally substituted azaheterocyclyl; or R1 and R2 in common with nitrogen and sulfur atoms to which they are bound form optionally substituted and optionally condensed with other cycles 1,1-dioxo-4H-pyrido[2,3-e][1,2,4]thiadiazine or optionally substituted and optionally condensed with other cycles 5,5-dioxo-5,6,7,9-tetrahydro-5-thia-1,6,9-triazabenzocyclohepten-8-one. Also, invention discloses methods for preparing different compounds of the general formula (1).

EFFECT: improved preparing methods, valuable medicinal properties of compounds.

10 cl, 4 sch, 4 tbl, 9 ex

FIELD: organic chemistry, biochemistry, pharmacy.

SUBSTANCE: invention relates to new heterocyclylsulfonyl alkylcarboxylic acids and their derivatives of the general formula (1): or their pharmaceutically acceptable salts, N-oxides or hydrates possessing the inhibitory effect on kinase activity and to the focused library for search of active leader-compounds comprising at least abovementioned compound. In the general formula 91) W represents optionally substituted heterocyclic radical, among them: pyrrole-3-yl, thiophene-2-yl, isooxazole-4-yl, pyrazole-4-yl, imidazole-4-yl, pyridine-3-yl, 1H-2,4-dioxopyrimidine-5-yl, 2,3-dihydro-1H-indole-5-yl, 2,3-dihydro-1H-indole-7-yl, 1,3-dihydro-2-oxoindole-5-yl, 2,3-dioxo-1H-indole-5-yl, 2-oxo-3H-benzoxazole-6-yl, benzothiazole-6-yl, 1H-benzimidazole-5-yl, benzo[1,2,5]oxadiazole-4-yl, benzo[1,2,5]thiadiazole-4-yl, 1,2,3,4-tetrahydroquinoline-6-yl, 3,4-dihydro-2-oxo-1H-quinoline-6-yl, quinoline-8-yl, 1,4-dihydro-2,3-dioxoquinoxaline-6-yl, 3-oxo-4H-benzo[1,4]oxazine-7-yl, 3-oxo-4H-benzo[1,4]thiazine-7-yl, 2,4-dioxo-1H-quinazoline-6-yl, 2,4-dioxo-1,5-dihydrobenzo[b][1,4]diazepine-7-yl or 2,5-dioxo-3,4-dihydrobenzo[b][1,4]diazepine-7-yl; Y represents optionally substituted methylene group; R1 represents chlorine atom, optionally substituted hydroxyl group, optionally substituted amino-group, optionally substituted azaheterocyclyl; n = 1, 2 or 3; or Yn represents carbon atom of optionally substituted (C3-C7)-cycloalkyl or optionally substituted (C4-C7)-heterocyclyl. Also, invention relates to a pharmaceutical composition in form of tablets, capsules or injections placed into pharmaceutically acceptable package.

EFFECT: valuable properties of compounds.

5 cl, 3 sch, 5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with the ways of extracorporal detoxication and treatment of hepatic failure. The method should be implemented due to introducing albumin-containing solution through a catheter into abdominal cavity at concentration of 30-40 g/l as dialyzing liquid for 2-4 h. This solution should be purified through "Artificial kidney" apparatus, coal sorbent and anion-exchange resin. Perfusion rate of albumin-containing solution in the course of its purification corresponds to 20-30 ml/min. Detoxication cycle with the help of albumin followed by its deligandization should be repeated many times. The innovation provides optimal mode of perfusion and, thus, high rate of toxins elimination through patient's peritoneum and excludes the necessity in applying anticoagulants and expensive "MARS" system.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with inspecific therapy of mastitis in cows to prevent the development of resistant races of microorganisms. One should intracisternally inject antiseptic preparation for mastitis-suffering cow as neutral anolyte with redox potential ranged +350 - +600 mV and concentration of oxidants being 150-350 mg/l by active chlorine obtained out of 0.3-0.5%-sodium chloride solution in diaphragmatic electrolysis due to impact of direct current of 1.5-5.0 A power and 16-32 V tension at current density being 500-550 A/sq. m. Moreover, antiseptic preparation should be introduced intracisternally into affected quarter of cow's udder at 10-15 sq. cm once-thrice daily for 2-5 d.

EFFECT: higher efficiency of therapy.

1 cl, 4 ex

The invention relates to medicine, namely to Nephrology, and is intended to improve the quality of life of renal patients with terminal renal insufficiency

The invention relates to medical equipment, namely to devices for hemodialysis

The invention relates to methods and devices for extracorporeal hemocorrection
The invention relates to medicine and can be used when working with hemofiltrate and plasma filters in the treatment of multiple organ failure and sepsis

The invention relates to the field of medicine and relates to a method of obtaining solutions for hemodialysis, used in medical practice on the artificial kidney" in the preparation of patients for organ transplantation, infectious diseases and intensive care units

The invention relates to medicine, in particular to the therapy, and can be used for cleaning plasma from the endo - and exogenous toxins

The invention relates to medicine and is intended for alternative inpatient care and self-help dialysis patients

The invention relates to medicine, namely to efferent methods of detoxification in Nephrology, and can be used during hemodialysis in children with unstable hemodynamics and young children with acute renal failure and poisoning

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to a method for preparing and purifying active hematin particles presenting in complexes hematin - saccharide and comprising complex of ferrous (III) - sodium gluconate in sucrose, complex ferrous (III) oxide hydrate - sucrose and complex ferrous (III) - saccharate. Method is developed on basis for separation of complex iron - saccharide from one or some filling agents and, preferably, by lyophilization. Isolation of complex iron - saccharide provides carrying out its analytical quantitative determination, additional concentrating or purifying as new useful product, preparing reconstructed preparations for new and useful medicinal agents. Capacity to isolating complex iron - saccharide responsible for hematin fraction including its lyophilized form is provided also by agents for preparing analytical material designated for control and proving the pharmacological unity, safety for patient and clinical indices of hematin complexes. Invention provides carrying out the analytical monitoring, standardization and control of quality during processes for producing hematin and for standardization in their using.

EFFECT: improved preparing method, valuable properties of end product.

45 cl, 2 tbl, 10 dwg, 11 ex

Up!